Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Illumina (ILMN – Research Report) today and set a price target of $125.00. The company’s shares closed last Friday at $127.10.
Arias covers the Healthcare sector, focusing on stocks such as Illumina, Agilent, and Bruker. According to TipRanks, Arias has an average return of -8.7% and a 40.36% success rate on recommended stocks.
In addition to Stifel Nicolaus, Illumina also received a Buy from Scotiabank’s Sung Ji Nam in a report issued today. However, on December 15, Bernstein upgraded Illumina (NASDAQ: ILMN) to a Hold.
See the top stocks recommended by analysts >>
Based on Illumina’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.12 billion and a GAAP net loss of $754 million. In comparison, last year the company earned a revenue of $1.12 billion and had a GAAP net loss of $3.82 billion
Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ILMN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Illumina (ILMN) Company Description:
Incorporated in 1998, Illumina, Inc. is a California-based company which develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The company’s products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting.
Read More on ILMN:
- Illumina (NASDAQ:ILMN) Divests Grail Following Years-Long Antitrust Battle
- Court sides with FTC finding Illumina-Grail deal anticompetitive, WSJ reports
- GE upgraded, Northrop Grumman downgraded: Wall Street’s top analyst calls
- Illumina just upgraded at Bernstein, here’s why
- Illumina upgraded to Market Perform from Underperform at Bernstein
